

TELOMERASE ACTIVITY IN CORD BLOOD

Thesis

*Submitted for Partial Fulfillment of the Master Degree in
Clinical Pathology*

Presented by

Asmaa Ahmed El Sayed
(M.B., B.Ch.)

Supervised by

Prof. Dr.Hala Mohamed Farawila

Professor of Clinical&Chemical Pathology
Faculty of Medicine
Cairo University

Prof. Dr.Nesrine Mohamed El Gharbawi

Assistant Professor of Clinical&Chemical Pathology
Faculty of Medicine
Cairo University

Prof. Dr. Hala Mufeed Said

Assistant Professor of Pediatrics
Faculty of Medicine
Cairo University

Faculty of Medicine

Cairo University

2007

Acknowledgment

*First and foremost thanks to Allah
The most beneficial and merciful*

*I would like to express my deepest gratitude and cordial thanks to **Prof. Dr.Hala Mohamed Farawila** Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her continuous help. To her I wish to express my deep thanks and utmost appreciation.*

*My sincere appreciation and special thanks are due to **Prof. Dr.Nesrine Mohamed El Gharbawi** Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her close supervision, indispensable directions and for the time she freely gave for guiding me throughout this study.*

*I am extremely grateful and thankful to **Prof. Dr. Hala Mufeed Said,** Assistant Professor of Pediatrics, Faculty of Medicine, Cairo University, for her kind supervision and generous cooperation.*

To a great Father

To my Mother, the source of hope in my life

To a precious Sisters

To a special Husband

To my sweet Kids

Abstract

Ex-vivo expansion of haematopoietic progenitor cells from umbilical cord blood is an interesting strategy to obtain a sufficient number of transplantable cells. Telomerase may contribute to the capacity for cell replication by compensating for telomere loss. Exploring the use of different cytokine combinations in increasing cellular replicative potential through telomerase activity may be useful for in vitro expansion of haematopoietic stem cells for transplantation. In this study, expansion of cord blood mononuclear cells was done in the presence of IL-3 and stem cell factor. Telomerase activity was assessed before and after one week of culture by a modified version of the telomeric repeat amplification protocol (TRAP). Cord blood samples expressed a basal level of telomerase activity which was increased in 80% of samples after expansion. However this increase did not reach a statistically significant level. The results of this work suggest that IL-3 and stem cell factor slightly increased telomerase activity of expanded cord blood cells. However, the addition of more cytokines to the culture might be useful to reach the optimal culture conditions allowing greater induction of telomerase activity and the generation of haematopoietic progenitor cells that retain their proliferative capacity.

List of Contents

Introduction and aim of work

Review of Literature:

Chapter I: Haematopoietic Stem Cell Transplantation

History.....	1
Stem cell models of haematopoiesis.....	3
Types of hematopoietic stem cell transplantation.....	5
Collection of stem cells.....	7
Conditioning regimens.....	11
Engraftment.....	12
Indication for hemopoietic stem cell transplantation.....	14
Outcome data.....	16
Complication of hematopoietic stem cell transplantation.....	20
Future of hematopoietic stem cell transplantation.....	35

Chapter II: Cord Blood Transplantation

Introduction.....	36
Characteristics of cord stem/progenitor cells.....	38
Clinical application.....	40
Collection of umbilical cord blood.....	42
Cryopreservation.....	44
Manipulation of umbilical cord blood.....	45
Cord blood banking.....	47
Ex-vivo expansion of human cord blood CD34+cells.....	48
Umbilical cord stem cells versus bone marrow and peripheral blood stem cells.....	49
Advantages of umbilical cord blood as hematopoietic stem cells for allogeneic transplantation.....	52
Disadvantages of umbilical cord blood transplantation.....	54
Ethical Quandary.....	55
Future directions of cord blood.....	57

Chapter III: Telomere and Telomerase

History.....	59
Structure of telomere.....	60
Telomeres and their function.....	61
Telomeres shortening.....	62

Telomeraseenzyme.....	64
Telomerase and cellular aging	66
Telomerase and Cell Cycle.....	67
Telomerase in normal tissues and in Cancer.....	69
Telomerase in hematopoietic cells and hematological malignancies.....	72
Telomerase and cancer treatment.....	78
 <i>Material and Methods</i>	81
<i>Results</i>	93
<i>Discussion</i>	102
<i>Summary and Conclusion</i>	110
<i>References</i>	111
<i>Arabic summary</i>	

List of Figures

Figure number	Figure Description	Page number
(1)	Principle of the Telo TAGGG Telomerase PCR ELISA ^{PLUS} .	85
(2)	Percentage of cord blood samples showing increased telomerase activity after ex-vivo expansion	97
(3)	Percentage of cord blood samples showing increased telomerase activity after ex-vivo expansion	98
(4)	Telomerase activity of cord blood samples before and after ex-vivo expansion	99
(5)	Correlation between telomerase activity of cord blood samples before expansion and after ex-vivo expansion	100
(6)	Correlation between basal telomerase activity in cord blood samples before expansion and fold increase after ex-vivo expansion.	101

List of Tables

Table number	Table Description	Page number
(1)	Clinical Characteristics with Various Sources of Stem Cells.	7
(2)	Common Indications for HSCT.	15
(3)	Five-Year Survival Data by Disease.	16
(4)	Clinical Classification of Acute Graft-versus-Host Disease According to Organ Injury.	27
(5)	Clinical features of chronic GVHD.	29
(6)	HPC content in UCB and BM HPC/ 10^5 nucleated cells.	39
(7)	Examples of disorders for which Cord blood transplantation has been utilized.	42
(8)	Telomerase activity in cord blood samples.	95
(9)	Telomerase activity in cord blood samples before and after ex-vivo expansion.	96
(10)	Percentage of cord blood samples showing increased telomerase activity after ex-vivo expansion.	97
(11)	Comparison between telomerase activity of cord blood samples before and after ex-vivo expansion.	99

(12)	Correlation between telomerase activity of cord blood samples before and after ex-vivo expansion.	100
(13)	Correlation between basal telomerase activity in cord blood samples before expansion and fold increase after ex-vivo expansion.	101

List of abbreviations

AA.....	Aplastic Anemia
ACD.....	Anticoagulant citrate dextrose.
ALL.....	Acute lymphoblastic leukemia.
AMD3100.....	An inhibitor of chemokine receptor 4 (CXCR4).
AML.....	Acute myeloid leukemia.
Anti-HCV	Anti-Hepatitis C virus
APB.....	Adult peripheral blood.
BCR.....	B cell antigen receptor.
BFU-E.....	Burst forming unit-Erythroid.
BFU-MK	Burst forming unit-Megakaryocyte.
BM	Bone marrow.
BMT.....	Bone marrow transplant.
CB.....	Cord blood.
CBSCT	Cord blood stem cell transplantation.
CBSCs.....	Cord blood stem cells.
CCG.....	A children's cancer group study.
CD	Cluster of differentiation.
CFC	Colony forming cells.
CFU-MK.....	Colony forming unit- megakaryocyte
CFU-GM.....	Colony forming unit-Granulocyte, Macrophage
CFU-GEMM.....	Colony forming unit-Granulocyte, Eosinophil, Macrophage, Megakaryocyte
CIBMTR.....	Center for International Blood and Marrow Transplant Research.
CLL	Chronic lymphocytic leukemia.
CML.....	Chronic myeloid leukemia

CMV.....Cytomegalovirus.
 CNSCentral nervous system.
 CR..... Complete response.
 CSC.....Cord stem cell.
 DCsDendritic cells.
 DIG..... Digoxigenin.
 DMSO.....Dimethyl sulfoxide.
 DNADeoxyribose Nucleic Acid.
 EBV-HLH..... Epstein-Barr virus associated hemophagocytic
 lymphohistiocytosis.
 ELISA..... The Enzyme-Linked ImmunoSorbent Assay.
 Epo.....Erythropoietin.
 EST.....Ever short telomere.
 FL.....Fetal liver.
 G-CSF.....Granulocyte colony stimulating factor.
 GM-CSF.....Granulocyte-macrophage colony stimulating factor.
 GVHD.....Graft versus host disease
 GVL.....Graft versus leukemia effect
 HBsAg..... Hepatitis B surfes antigen
 HCAb.....Hepatitis C antibody
 HCL.....Hairy cell leukemia.
 HEPA..... High Efficiency Particulate Air (filter/mask).
 HES.....Hydroxyethyl starch
 HLA..... Human leucocytic antigen
 HPC.....Haematopoietic progenitor cell.
 HRP..... Horseradish peroxidase
 HSC.....Hematopoietic stem cell
 HSCT.....Hematopoietic Stem Cell Transplantation
 HSPC.....Hematopoietic stem/progenitor cells

hTERT.....	Human Telomerase Reverse Transcriptase
hTR.....	Human telomerase RNA component
IGF-I.....	Insulin-like growth factor-1.
IS.....	Internal standard.
IL-2.....	Interleukin-2.
IL-3.....	Interleukin-3.
IL-4.....	Interleukin-4.
IL-5.....	Interleukin-5.
IL-6.....	Interleukin-6.
Kbp.....	Kilobasepairs.
LTC-ICs.....	Long term culture initiating cells.
MCL.....	Mantle cell lymphoma.
MDS	Myelodysplastic Syndrome.
MoAb.....	Monoclonal antibody.
MM.....	Multiple myeloma.
MMF.....	Mycophenolate mofetil
MNCs.....	Mononuclear cells.
MTP.....	Microtiter plate.
NA.....	Not applicable.
NMDP.....	The National Marrow Donor Program.
PB.....	Peripheral blood.
PBSCT.....	Peripheral blood stem cell transplantation.
PCR.....	Polymerase chain reaction.
PNAs.....	Peptide nucleic acids.
RBCs.....	Red blood Corpuscle.
rh G-CSF.....	Recombinant human granulocyte colony-stimulating factor.
rh GM-CSF.....	Recombinant human granulocyte-macrophage colony-stimulating factor.

rh SCF.....Recombinant human stem cell factor.
RNARibose Nucleic Acid.
SCF..... Stem cell factor.
STF..... flt3/flk2 ligand.
TBITotal-body irradiation.
TCR..... T cell receptor.
TMB.....Tetramethylbenzidine.
TNF..... Tumor necrosis factor.
TP1..... Telomerase-associated protein 1.
Tpo..... Thrombopoietin.
TRAP.....Telomeric repeat amplification protocol.
TRF.....Telomere restriction fragments.
Trf1P.....Telomeric repeat binding factors-1.
Trf2P.....Telomeric repeat binding factors-2.
TRLI.....Transplantation-related lung injury.
UCB..... Umbilical cord blood.
UCBT..... Umbilical cord blood transplantation.
VOD..... Veno-occlusive disease.
WBC..... White blood cell.

Introduction
And
Aim of work

Introduction & Aim of the Work

Stem cells possess the unique ability of self-renewal and multilineage differentiation. These combined properties are reflected in the ability of a hematopoietic stem cell (HSC) to completely and durably reconstitute hematopoiesis of a myeloablated recipient and maintain it throughout the entire life span (*Kondo et al., 2003*).

HSC self-renewal is not a perfect process and daughter cells have progressively reduced proliferative capacity, due in part to progressive telomere erosion with each cell division. The length of telomeres decreases with increase in age in vivo and with cell division in vitro in haemopoietic stem cell (*Vaziri et al., 1994*). This, in turn, leads to proliferative senescence that can be observed both in vivo and in vitro.

Telomeres are structures at the end of eukaryotic chromosomes that protect chromosomes from degradation, fusion, and recombination. In mammalian cells, they consist of hexanucleotide (TTAGGG) repeats and several associated protein components. In the absence of compensatory mechanisms, dividing cells undergo gradual telomere erosion. When telomeres reach a critical degree of shortening, cells recognize this as DNA damage and initiate proapoptotic programs or enter senescence (*Granger et al., 2002*).

Human telomerase, an RNA-dependent DNA polymerase, can compensate for the loss of telomere length by synthesizing new telomeric repeats (TTAGGG) _n, complimentary to human telomerase RNA component (hTR) (*Feng et al., 1995*). Telomerase is a ribonucleoprotein complex consisting of an RNA template complementary of telomeric